Tuesday, 7 December 2004
14:00 - 14:30
Development of a novel multi-biomarker panel for diagnosis of early stage ovarian cancer through the use of Ciphergen’s PatternTrackTM Process
Paul Smith, European Director, Ciphergen Biosystems Inc
A multi-site study directed by Dr. Daniel Chan in the Department of Pathology at Johns Hopkins Medical Institute was conducted to discover novel biomarkers of early stage ovarian cancer. Ciphergen’s Pattern Track process enabled rapid discovery, validation, identification and characterization of “patterns” of differentially expressed proteins present in patient serum. Serum samples from over 200 patients with ovarian cancer were collected from five medical institutes for cross-validation and immunoassay based confirmation to ensure biomarker association with ovarian cancer. Three biomarkers were discovered and identified as apolipoprotein A1, a truncated form of transthyretin, and a cleavage fragment of inter-a-trypsin inhibitor heavy chain H4. By combining the three biomarkers with CA125, early stage ovarian cancer was detected with sensitivity and specificity values significantly better than current tests of CA125 alone. This multi-variate biomarker model provides the basis for a diagnostic assay for the detection of early stage ovarian cancer.
Zhang, Z. et al (2004) “Three biomarkers identified from serum proteomic analysis for the detection of early stage”
